Brain-computer interface (BCI) concept stocks saw a significant rally. At the time of writing, BRAINAURORA-B (06681) surged over 31%, trading at HK$4. MicroPort NeuroTech (02172) rose more than 5% to HK$9.4, while Nanjing Panda Electronics (00553) gained over 5%, reaching HK$4.8.

The surge follows a key development announced on May 18th. China has officially initiated a multi-center clinical trial for its first fully implanted 128-channel BCI system. The trial, led by Beijing Tiantan Hospital affiliated with Capital Medical University, marks a critical acceleration in the clinical translation of domestically developed, fully invasive BCI technology. This advancement paves the way for new rehabilitation methods for patients with quadriplegia.

Analysts from BOCI Research previously noted that the BCI industry is at a pivotal juncture, transitioning from laboratory breakthroughs to commercial application. With rapid progress across three major technological pathways, the market is poised for significant expansion. The industry's supply chain is maturing, featuring high barriers to entry for upstream core components and substantial application potential, particularly in the medical downstream sector. The industry holds long-term potential to grow from a multi-billion to a multi-trillion yuan scale. Supported by continuous favorable policies and accelerating commercialization, the long-term growth prospects for the BCI sector remain highly positive.